Catalyst Edge · Scanner · Tickers · ACAD
CATALYST DOSSIER · UPDATED 2026-09-25

$ACAD

biotech · convergence 6 · conviction WATCH
Convergence Score
6
Conviction
WATCH
Signals Firing
9
Quick tools:🃏 Swipe deck🎯 Today verdict

Price & Live Quote

Loading live quote & chart…

Practice trade tools

Build a reference frame, save a practice trade, or preview a draft. No brokerage order is placed.

Paper trade unavailable: missing risk-bounded frame

Reference only. Not financial advice. No brokerage order is placed.

Why $ACAD?

ACAD 6 WATCH biotech

Quantitative

  • Net Income (CY2026Q2): $31.5M (+18.1% YoY)

Catalysts

  • Multi-spoke convergence: 9 convergent signals fired: alpha, biotech, sec_fda, auto_edgar_fulltext, auto_sec_audit

Risks

  • Auditor change / restatement: restatement on

Bear case

  • Multiple compression: If breadth deteriorates, biotech-wide multiples re-rate lower regardless of pick-specific thesis

Sympathy basket (cerebro)

  • OPEN via real_estate r=+0.95 sympathetic (score 8)
  • AEI via real_estate r=+0.95 sympathetic (score 7)
  • NFE via utilities r=+0.94 sympathetic (score 51)
  • EVRG via utilities r=+0.94 sympathetic (score 25)
  • REZI via consumer r=+0.90 sympathetic (score 27)
  • NXXT via consumer r=+0.90 sympathetic (score 22)

Finance Desk Verdict

Independent agent review — valuation, statement audit, and earnings read on the latest filing.

Valuation: unclearAudit: cleanDesk score: 32/100

Reg FD / Other Events 8-K from a commercial-stage CNS pharma with two approved drugs; exhibit text is uncached so the catalyst is unconfirmed, and weak momentum (26) combined with null market cap and no financial data in the bundle prevents higher conviction — pass until the EX-99.1 content is verified.

Bull case: Two de-risked commercial products reduce binary pipeline dependency. If EX-99.1 discloses a pipeline advancement (e.g., Phase 2/3 readout in schizophrenia or another CNS indication), a business development deal, or DAYBUE uptake acceleration, the stock could re-rate sharply from a depressed $22 base. Low momentum may signal an oversold setup coiling ahead of a positive print.

Bear case: NUPLAZID carries a legacy FDA mortality-signal scrutiny history in elderly dementia-related psychosis patients. DAYBUE's commercial ramp has been capital-intensive with slow net revenue growth. Momentum of 26 may reflect informed distribution ahead of disappointing commercial guidance, a pipeline failure, or further label/safety review disclosure hidden in the uncached EX-99.1.

Signals Firing

alphabiotechsec_fdaauto_edgar_fulltextauto_sec_auditauto_setup_classifierauto_macro_edgar_ftsauto_macro_ofac_sanctionsauto_macro_options_gex
Each tag is a spoke that flagged this ticker today. Weights tuned weekly against published outcomes.

Recent SEC Filings

Sympathy Basket

Tickers Catalyst Edge tracks as moving with this name. Cross-correlation derived from sector + score-cohort proximity.

Earnings Catalyst

No recent earnings event.

Auto-generated from public filings + tier-1 wires. Catalyst Edge publishes its picks and its losses — see the trust report and methodology. Not financial advice. Confirm independently before trading.

You came here for ACAD. You found it after it moved, the same way everyone else did.

$99 once — every ticker on this site ranked before the open.

Tier 1 setups touched +2% intraday 48.7% of the time across 355 tracked calls. Baseline for everything else: 40.2%. That is a +8.5 point edge, measured from the NEXT OPEN — the first price you could actually pay, not the prior close. We publish the misses too: https://catalystedgescanner.com/trust/

  1. Click Become a Founding Member below.
  2. Pay $99 once — not monthly, not ever again.
  3. You keep every future release at that price. Tomorrow's ranked list lands at 3:30 AM ET, before the open.

29 of 30 founding seats left. The price goes up when they are gone.

Become a Founding Member — $99 once

One payment, access for as long as we run the service. The free daily picks stay free — this is for people who want the full console. Not buying today? Get tomorrow's ranked list free →